![]() | |
Clinical data | |
---|---|
Pronunciation | /duːˌkrævəˈsɪtɪnɪb/ doo-KRA-və-SI-ti-nib |
Trade names | Sotyktu |
Other names | BMS-986165 |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Tyrosine kinase 2 (TYK2) inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 99% |
Protein binding | 82–90% |
Metabolism | Liver (primarily CYP1A2) |
Metabolites | BMT-153261 (active) |
Elimination half-life | 10 hours |
Excretion | Feces, urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.329.069 |
Chemical and physical data | |
Formula | C20H19D3N8O3 |
Molar mass | 425.466 g·mol−1 |
3D model (JSmol) | |
| |
|
Deucravacitinib, sold under the brand name Sotyktu, is a medication used for the treatment of moderate-to-severe plaque psoriasis. [7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth. [7] It was developed by Bristol Myers Squibb. [10]
Deucravacitinib was approved for medical use in the United States in September 2022, [7] [11] [12] and in Australia in December 2022. [1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [13] [14]
Deucravacitinib is indicated for the treatment of adults with moderate-to-severe plaque psoriasis. [7]
It acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2). [15]
The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms are replaced by deuterium. [16]
In January 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis. [8] [17] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG. [8] [17] Deucravacitinib was approved for medical use in the European Union in March 2023. [8]